Navigation Links
Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
Date:1/17/2008

ctions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
2. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
3. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
4. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
5. Wyeth Declares Preferred Stock Dividend
6. Wyeth Announces Election of New Principal Corporate Officer
7. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
8. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
9. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
10. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
11. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Global Biologics and Biosimilars Industry ... , The Global Biologics and Biosimilars ... study on the current state of the biologics ... a basic overview of the industry including definitions, ...
(Date:3/4/2015)... , March 4, 2015 AcelRx ... specialty pharmaceutical company focused on the development and ... acute and breakthrough pain, today announced that it ... results after market close on Monday, March 9th, ... call at 4:30 p.m. Eastern Time (1:30 p.m. ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ,SARAH, ... yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma ... late 2016.   SARAH, a large French ... (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding ...
(Date:3/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... Miami, FL on March 10, 2015 at ... Chief Financial Officer, will provide a corporate overview. ... Halozyme,s corporate website at www.halozyme.com , and a recording ... To access the live webcast, please log on to Halozyme,s ...
Breaking Biology Technology:Global Biologics and Biosimilars Industry Report 2015-2020 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
... Energy is the biggest challenge in the world, and we ... of energy inefficiencies can be attributed to transportation (27 percent), ... calculated by the U.S. Energy Information Administration statistics ... G.P. Yeh of Fermi Labs . He also said ...
... Madison, Wis. - As the completion of an audit ... has abandoned another costly IT project. , ,According to a ... Department of Workforce Development has decided to stop ... track unemployment claims. The system, known as Enhanced Automated Benefits ...
... fellow travelers a thing or two about commuting. , ,The ... an executive-in-residence and one of its portfolio companies, Caden ... , Gregg Fergus And since Fergus has been ... his new posts reduce the distance between home and work. ...
Cached Biology Technology:Energy conservation might take us farther than renewable fuels 2Energy conservation might take us farther than renewable fuels 3Energy conservation might take us farther than renewable fuels 4Energy conservation might take us farther than renewable fuels 5Energy conservation might take us farther than renewable fuels 6State of Wisconsin dumps another tech project 2Biotech executive books a career flight that's closer to home 2Biotech executive books a career flight that's closer to home 3
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... in the November 2008 issue of BioScience ... an Era of Genomics and Proteomics. David Emerson, Liane ... genomics and proteomics are changing techniques used for identifying ... levels of discrimination, but standards for their use must ...
... known that it,s possible for one gene to produce slightly ... certain sequences from the messenger RNA. Now, an MIT team ... both far more prevalent and varies more between tissues than ... 94 percent, generate more than one form of their protein ...
... to immune system cells called T-lymphocytes that target a ... fight a form of childhood cancer called neuroblastoma, said ... Hospital in a report that appears online today in ... a way to convert a naturally occurring problem into ...
Cached Biology News:BioScience tip sheet, November 2008 2Human genes sing different tunes in different tissues 2A double-barreled immune cell approach for neuroblastoma 2
Request Info...
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Biology Products: